There is one variable that can throw a wrench into a gastroenterologist's endoscopy day; how long it takes to navigate a colonoscope to the cecum. This is a function of the tortuosity of the colon. Softscope Medical Technologies is developing two products; Tempo, for the colon, and Tempo SB, for the small bowel, to take some of the challenges out of the two procedures. Each product is a disposable propulsive assist device designed as an endoscopic accessory, configured as a short attachment that fits quickly and simply over existing colonoscopes and enteroscopes to aid advancement. Softscope's products work by a principle that the company calls Continuous Rolling Over Sleeve (CROS) technology whereby a rotating membrane tube helps propel an endoscope around and through the GI tract. The rotating membrane tube is driven by a mechanical rotating drive wire. According to Softscope, its devices don't interfere with visualization, tip deflection, suction, the performance of therapeutic accessories, or the overall "feel" of the endoscope.
6110 Blue Circle Drive
Suite 220
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
The US FDA’s device center sent warning letters to three domestic device manufacturers and one German firm for failing to adhere to protocol on several issues.
Cardiosense has launched a nationwide clinical study, SEISMIC-HF II, to validate its non-invasive, AI-powered technology for monitoring heart failure. The data will be used to file for US regulatory clearance of the Cardiosense heart failure monitoring platform.
Valued at over $1.9bn, ConcertAI is building on its pre-existing multi-agentic AI SaaS solution CARAai to bring life science customers the new Precision suite of applications: Precision Explorer, Precision Trials, Precision GTM and Precision360.
